{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:24:13Z","timestamp":1762431853350,"version":"3.40.5"},"reference-count":12,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,30]]},"DOI":"10.20945\/2359-3997000000221","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T13:36:35Z","timestamp":1586352995000},"source":"Crossref","is-referenced-by-count":6,"title":["Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy"],"prefix":"10.20945","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1166-3198","authenticated-orcid":false,"given":"Lucia","family":"Brilli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3044-0889","authenticated-orcid":false,"given":"Luana","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7848-6261","authenticated-orcid":false,"given":"Michele","family":"Campanile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1171-6384","authenticated-orcid":false,"given":"Tania","family":"Pilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-3396","authenticated-orcid":false,"given":"Cristina","family":"Agostinis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4753-6649","authenticated-orcid":false,"given":"Alfonso","family":"Cerase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-6321","authenticated-orcid":false,"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-1751","authenticated-orcid":false,"given":"Maria Grazia","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8510","reference":[{"issue":"1","key":"key20200408093631_B1","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","unstructured":".Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;23;6(1):8.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"key20200408093631_B2","doi-asserted-by":"crossref","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","unstructured":".Cukier P, Santini FC, Scaranti M, Hoff AO. Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer. 2017;24(12):T331-T347.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"key20200408093631_B3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy \u2013 immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Bun","year":"2017","unstructured":".Bun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy \u2013 immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4):195-207.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"key20200408093631_B4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","unstructured":".Faje A.Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19(1):82-92.","journal-title":"Pituitary"},{"issue":"4","key":"key20200408093631_B5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/CCO.0000000000000293","article-title":"Endocrinological side-effects of immune checkpoint inhibitors","volume":"28","author":"Torino","year":"2016","unstructured":".Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol. 2016;28(4):278-87.","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"key20200408093631_B6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","unstructured":".Albarel F, Gaudy C, Castinetti F, Carr\u00e9 T, Morange I, Conte-Devolx B,  et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172(2):195-204.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"key20200408093631_B7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12020-017-1289-2","article-title":"Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab","volume":"58","author":"Brilli","year":"2017","unstructured":".Brilli L, Danielli R, Ciuoli C, Calabr\u00f2 L, Di Giacomo AM, Cerase A,  et al. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine. 2017;58(3):535-41.","journal-title":"Endocrine"},{"issue":"1","key":"key20200408093631_B8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Fleseriu M Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","unstructured":".Dillard T, Yedinak CG, Alumkal J, Fleseriu M Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13(1):29-38.","journal-title":"Pituitary"},{"issue":"2","key":"key20200408093631_B9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1 Treatment Induced Central Diabetes Insipidus","volume":"103","author":"Zhao","year":"2018","unstructured":".Zhao C, Tella SH, Del Rivero J, Kommalapati A, Ebenuwa I, Gulley J,  et al. Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. J Clin Endocrinol Metab. 2018;103(2):365-9.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"key20200408093631_B10","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.6004\/jnccn.2014.0105","article-title":"Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash","volume":"12","author":"Nallapaneni","year":"2014","unstructured":".Nallapaneni NN, Mourya R, Bhatt VR, Malhotra S, Ganti AK, Tendulkar KK. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J Natl Compr Canc Netw. 2014;12(8):1077-81.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"key20200408093631_B11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2019","volume":"17","author":"Thompson","year":"2019","unstructured":".Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S,  et al. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019;17(3):255-89.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"key20200408093631_B12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3171\/2013.11.JNS131320","article-title":"Normal dimensions of the posterior pituitary bright spot on magnetic resonance imaging","volume":"120","author":"C\u00f4t\u00e9","year":"2014","unstructured":".C\u00f4t\u00e9 M, Salzman KL, Sorour M, Couldwell WT. Normal dimensions of the posterior pituitary bright spot on magnetic resonance imaging. J Neurosurg. 2014;120(2):357-62.","journal-title":"J Neurosurg"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T13:36:48Z","timestamp":1586353008000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S2359-39972020005002203&lng=en&nrm=iso"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":12,"alternative-id":["10.20945\/2359-3997000000221"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000221","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"type":"print","value":"2359-3997"},{"type":"electronic","value":"2359-4292"}],"subject":[],"published":{"date-parts":[[2020,3,30]]}}}